[go: up one dir, main page]

UA99093C2 - Применение фенофибрата или его производного для лечения диабетической ретинопатии - Google Patents

Применение фенофибрата или его производного для лечения диабетической ретинопатии

Info

Publication number
UA99093C2
UA99093C2 UAA200805980A UAA200805980A UA99093C2 UA 99093 C2 UA99093 C2 UA 99093C2 UA A200805980 A UAA200805980 A UA A200805980A UA A200805980 A UAA200805980 A UA A200805980A UA 99093 C2 UA99093 C2 UA 99093C2
Authority
UA
Ukraine
Prior art keywords
fenofibrate
derivative
treatment
diabetic retinopathy
retinopathy
Prior art date
Application number
UAA200805980A
Other languages
English (en)
Ukrainian (uk)
Inventor
Жан-Клод Анске
Энтони Кич
Original Assignee
Лабораториз Фурнье С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36130110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA99093(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лабораториз Фурнье С.А. filed Critical Лабораториз Фурнье С.А.
Publication of UA99093C2 publication Critical patent/UA99093C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение касается применения фенофибрата или его производного в изготовлении лекарства для лечения ретинопатии.
UAA200805980A 2005-11-10 2006-11-10 Применение фенофибрата или его производного для лечения диабетической ретинопатии UA99093C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05292388A EP1785133A1 (en) 2005-11-10 2005-11-10 Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy

Publications (1)

Publication Number Publication Date
UA99093C2 true UA99093C2 (ru) 2012-07-25

Family

ID=36130110

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200805980A UA99093C2 (ru) 2005-11-10 2006-11-10 Применение фенофибрата или его производного для лечения диабетической ретинопатии

Country Status (18)

Country Link
US (1) US20090170939A1 (ru)
EP (3) EP1785133A1 (ru)
JP (1) JP5171635B2 (ru)
KR (1) KR20080074877A (ru)
CN (2) CN101304742A (ru)
AU (1) AU2006313711B2 (ru)
BR (1) BRPI0618283A2 (ru)
CA (1) CA2628508C (ru)
EA (1) EA014755B1 (ru)
ES (2) ES2805227T3 (ru)
HU (2) HUE030936T2 (ru)
IL (1) IL191208A (ru)
LT (1) LT3167882T (ru)
PL (2) PL1954261T3 (ru)
PT (2) PT1954261T (ru)
SI (1) SI3167882T1 (ru)
UA (1) UA99093C2 (ru)
WO (1) WO2007054566A2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102304103A (zh) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸盐、制备方法、药物组合物及应用
CN105764533A (zh) * 2013-10-25 2016-07-13 儿童医疗中心有限公司 治疗或预防视网膜血管疾病的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494112B1 (ru) 1980-11-19 1986-01-10 Laruelle Claude
FR2602423B1 (fr) 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
DE19608750A1 (de) 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
ZA200302507B (en) * 2000-10-12 2004-03-31 Nisaan Chemical Ind Ltd Preventives and remedies for complications of diabetes.
CN1220488C (zh) * 2000-10-26 2005-09-28 爱尔兰福尼雅实验室有限公司 用于治疗内皮机能障碍的非诺贝特和辅酶q10组合物
ATE357216T1 (de) 2001-02-22 2007-04-15 Jagotec Ag Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
EP1381361B1 (en) * 2001-04-04 2009-02-25 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
CA2505771A1 (en) * 2002-12-10 2004-06-24 Novartis Ag Combination of an dpp-iv inhibitor and a ppar-alpha compound
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US7319170B2 (en) * 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
CA2555316A1 (en) * 2004-02-09 2005-08-18 Aska Pharmaceutical Co., Ltd. Combined pharmaceutical composition

Also Published As

Publication number Publication date
PT3167882T (pt) 2020-07-13
CN103417524A (zh) 2013-12-04
EA200801023A1 (ru) 2008-10-30
EP3167882B1 (en) 2020-04-08
EP3167882A1 (en) 2017-05-17
PL3167882T3 (pl) 2020-11-16
IL191208A0 (en) 2009-08-03
HUE030936T2 (en) 2017-06-28
EA014755B1 (ru) 2011-02-28
WO2007054566A3 (en) 2007-08-23
ES2605025T3 (es) 2017-03-10
HUE050045T2 (hu) 2020-11-30
IL191208A (en) 2017-08-31
KR20080074877A (ko) 2008-08-13
AU2006313711B2 (en) 2012-02-23
BRPI0618283A2 (pt) 2012-02-28
PT1954261T (pt) 2016-11-29
CA2628508C (en) 2013-11-12
WO2007054566A2 (en) 2007-05-18
AU2006313711A1 (en) 2007-05-18
CA2628508A1 (en) 2007-05-18
JP5171635B2 (ja) 2013-03-27
EP1954261A2 (en) 2008-08-13
AU2006313711A9 (en) 2021-04-01
LT3167882T (lt) 2020-07-27
SI3167882T1 (sl) 2020-09-30
CN101304742A (zh) 2008-11-12
JP2009515856A (ja) 2009-04-16
ES2805227T3 (es) 2021-02-11
EP1785133A1 (en) 2007-05-16
US20090170939A1 (en) 2009-07-02
PL1954261T3 (pl) 2017-07-31
EP1954261B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
MX2007012538A (es) Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.
HK1129594A1 (en) Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
IL201479A (en) Use of tapentadol for the preparation of pain medication
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
IL160420A0 (en) Treating or preventing diabetes with cannabidiol
ZA200809250B (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
TNSN08400A1 (en) Organic compounds and their uses
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
EP2084178A4 (en) CONJUGATES OF CYTOTOXIC COMPOUNDS WITH PEPTIDES
UA99093C2 (ru) Применение фенофибрата или его производного для лечения диабетической ретинопатии
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate
EA201000738A1 (ru) Медицинское применение 3-(2,2,2-триметилгидразиниум)пропионат гидрофумарата и дигидрофосфата
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
MX2009004237A (es) Uso de timosina alfa 1 para la preparacion de un medicamento para la prevencion y tratamiento de alergias.
PL1838392T3 (pl) Leki zawierające selen na śródbłonkowe choroby układu naczyniowego
MX2007004040A (es) Uso para alfa-simpatomimeticos con estructura de 2-imidazolina.
UA87224C2 (ru) Применение 24-нор-урсодеоксихолевой кислоты для лечения холестатических заболеваний печени
MX2009002091A (es) Metodos para reducir las concentraciones de glucosa.
UA32882U (ru) Способ профилактики и терапевтического лечения различных заболеваний